Veradermics, Incorporated (MANE) Cash Flow Statement
Veradermics, Incorporated (MANE) generated -$78.3M of operating cash flow over the twelve months to 2026-06-30, spent $26000 on capital expenditure and had free cash flow of -$78.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MANEVeradermics, IncorporatedFollow MANE — free
—
Price chart with a free account
- Market cap
- 5.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -23.7 | -71.6 | -78.3 | |
| Capital expenditure | 0.0 | 0.0 | -0.0 | |
| Free cash flow | -23.7 | -71.6 | -78.3 | |
| Stock-based compensation | 0.3 | 1.4 | — |
USD millions · SEC XBRL
Veradermics, Incorporated — questions
- What is Veradermics, Incorporated's operating cash flow?
- -$78.3M over the twelve months to 2026-06-30.
- How much does Veradermics, Incorporated spend on capital expenditure?
- $26000 over the twelve months to 2026-06-30.
- What is Veradermics, Incorporated's free cash flow?
- -$78.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Veradermics, Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.